These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30351228)

  • 1. Development of a Chemiluminescent ELISA Method for the Detection of Total Anti-Adeno Associated Virus Serotype 9 (AAV9) Antibodies.
    Kavita U; Dai Y; Salvador L; Miller W; Adam LP; Levesque PC; Zhang YJ; Ji QC; Pillutla RC
    Hum Gene Ther Methods; 2018 Dec; 29(6):237-250. PubMed ID: 30351228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structurally Mapping Antigenic Epitopes of Adeno-associated Virus 9: Development of Antibody Escape Variants.
    Emmanuel SN; Smith JK; Hsi J; Tseng YS; Kaplan M; Mietzsch M; Chipman P; Asokan A; McKenna R; Agbandje-McKenna M
    J Virol; 2022 Feb; 96(3):e0125121. PubMed ID: 34757842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping an Adeno-associated Virus 9-Specific Neutralizing Epitope To Develop Next-Generation Gene Delivery Vectors.
    Giles AR; Govindasamy L; Somanathan S; Wilson JM
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30089698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation and characterization of anti-Adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies.
    Tseng YS; Vliet KV; Rao L; McKenna R; Byrne BJ; Asokan A; Agbandje-McKenna M
    J Virol Methods; 2016 Oct; 236():105-110. PubMed ID: 27424005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive
    Kruzik A; Koppensteiner H; Fetahagic D; Hartlieb B; Dorn S; Romeder-Finger S; Coulibaly S; Weber A; Hoellriegl W; Horling FM; Scheiflinger F; Reipert BM; de la Rosa M
    Hum Gene Ther Methods; 2019 Apr; 30(2):35-43. PubMed ID: 30734588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Study of Aavrh.10 Receptor and Antibody Interactions.
    Mietzsch M; Yu JC; Hsi J; Chipman P; Broecker F; Fuming Z; Linhardt RJ; Seeberger PH; Heilbronn R; McKenna R; Agbandje-McKenna M
    J Virol; 2021 Nov; 95(23):e0124921. PubMed ID: 34549984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modifiers of Adeno-Associated Virus-Mediated Gene Expression in Implication for Serotype-Universal Neutralizing Antibody Assay.
    Krotova K; Aslanidi G
    Hum Gene Ther; 2020 Oct; 31(19-20):1124-1131. PubMed ID: 32495655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adeno-associated virus serotype 1 (AAV1)- and AAV5-antibody complex structures reveal evolutionary commonalities in parvovirus antigenic reactivity.
    Tseng YS; Gurda BL; Chipman P; McKenna R; Afione S; Chiorini JA; Muzyczka N; Olson NH; Baker TS; Kleinschmidt J; Agbandje-McKenna M
    J Virol; 2015 Feb; 89(3):1794-808. PubMed ID: 25410874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia.
    Harrington EA; Sloan JL; Manoli I; Chandler RJ; Schneider M; McGuire PJ; Calcedo R; Wilson JM; Venditti CP
    Hum Gene Ther; 2016 May; 27(5):345-53. PubMed ID: 26790480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A convenient enzyme-linked immunosorbent assay for rapid screening of anti-adeno-associated virus neutralizing antibodies.
    Ito T; Yamamoto S; Hayashi T; Kodera M; Mizukami H; Ozawa K; Muramatsu S
    Ann Clin Biochem; 2009 Nov; 46(Pt 6):508-10. PubMed ID: 19729501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of Anti-Adeno-Associated Virus Serotype 9 Antibodies in Adult Patients with Spinal Muscular Atrophy.
    Stolte B; Schreiber-Katz O; Günther R; Wurster CD; Petri S; Osmanovic A; Freigang M; Uzelac Z; Leo M; von Velsen O; Bayer W; Dittmer U; Kleinschnitz C; Hagenacker T
    Hum Gene Ther; 2022 Sep; 33(17-18):968-976. PubMed ID: 35943879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays.
    Gorovits B; Fiscella M; Havert M; Koren E; Long B; Milton M; Purushothama S
    AAPS J; 2020 Jan; 22(2):24. PubMed ID: 31907680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroprevalence of adeno-associated virus types 1, 2, 3, 4, 5, 6, 8, and 9 in a Basque cohort of healthy donors.
    Navarro-Oliveros M; Vidaurrazaga A; Soares Guerra G; Castellana D; Embade N; Millet O; Marigorta UM; Abrescia NGA
    Sci Rep; 2024 Jul; 14(1):15941. PubMed ID: 38987633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of Neutralizing Antibodies against Adeno-Associated Virus Serotypes 1, 2, and 9 in Non-Injected Latin American Patients with Heart Failure-ANVIAS Study.
    Sierra-Delgado JA; Likhite S; Bautista PK; Gómez-Ochoa SA; Echeverría LE; Guío E; Vargas C; Serrano NC; Meyer KC; Rincon MY
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using an In Vivo Mouse Model to Determine the Exclusion Criteria of Preexisting Anti-AAV9 Neutralizing Antibody Titer of Pompe Disease Patients in Clinical Trials.
    Wang H; Zhang C; Dong Z; Zhu X; Zheng X; Liu Z; Zhou J; Yu S; Wu X; Dong X
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Prevalence of Antibodies Against Adeno-Associated Virus in Healthy Children and Patients with Mucopolysaccharidosis III: Perspective for AAV-Mediated Gene Therapy.
    Fu H; Meadows AS; Pineda RJ; Kunkler KL; Truxal KV; McBride KL; Flanigan KM; McCarty DM
    Hum Gene Ther Clin Dev; 2017 Dec; 28(4):187-196. PubMed ID: 29064732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing Antibodies Against Adeno-Associated Virus (AAV): Measurement and Influence on Retinal Gene Delivery.
    Desrosiers M; Dalkara D
    Methods Mol Biol; 2018; 1715():225-238. PubMed ID: 29188517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in Humans.
    Ellsworth JL; O'Callaghan M; Rubin H; Seymour A
    Hum Gene Ther Clin Dev; 2018 Mar; 29(1):60-67. PubMed ID: 29624457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A strategy for high antibody expression with low anti-drug antibodies using AAV9 vectors.
    Davis-Gardner ME; Weber JA; Xie J; Pekrun K; Alexander EA; Weisgrau KL; Furlott JR; Rakasz EG; Kay MA; Gao G; Farzan M; Gardner MR
    Front Immunol; 2023; 14():1105617. PubMed ID: 37153616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.